RPL28

Across TCGA pan-cancer cohorts, RPL28 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RPL28 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RPL28 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL28 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where RPL28 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	21	view →
UCEC	DFS	Quartile	III,IV	1.000	0.269	.008	20	view →
LUAD	DFS	Quartile	All	0.945	0.474	.003	11	view →
OV	DFS	Median	All	0.573	0.942	.006	8	view →
CCRCC	DFS	Quartile	All	0.584	0.820	.013	7	view →
GBM	DFS	Median	All	0.270	0.463	.006	5	view →
HNSC	OS	Median	All	0.988	0.946	.036	4	view →
LSCC	OS	Median	II,III,IV	1.000	0.883	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RPL28–PDAC (DFS)

Open the PDAC breakdown →